Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TAF1 | P21675 | 1/20 | 0.30 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179801 | 0.81 | AHR (0.41) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL21982935 | 0.78 | AHR (0.41) | AHRNR4A2CSNK2A1NR3C1PGR | |
| SCHEMBL3584001 | 0.75 | AHR (0.45) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL8995163 | 0.74 | AHR (0.48) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL26389475 | 0.72 | AHR (0.47) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL2301175 | 0.72 | BRD4 (0.43) | AHRCYP2A6NR4A2BRD4 | |
| SCHEMBL18746334 | 0.71 | SMN1; SMN2 (0.51) | — | |
| SCHEMBL564695 | 0.71 | AHR (0.50) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL2380876 | 0.71 | AHR (0.45) | AHRCYP2A6NR4A2PIM3CSNK2A1 | |
| SCHEMBL120501 | 0.71 | AHR (0.45) | AHRCYP2A6NR4A2PIM3CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260052832-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| CN-109328059-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | AHR 3335/4885CYP2A6 1748/4885NR4A2 2847/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | AHR 3335/4885CYP2A6 1748/4885NR4A2 2847/4885 |
| US-20260052832-A1 | COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE | ETV1, L1CAM, CCNT1 | AHR 2951/4885CYP2A6 4535/4885NR4A2 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.